Alpha Tau Medical (NasdaqCM:DRTS) is back in focus after reporting clinical data showing a 100% objective response rate for its Alpha DaRT plus pembrolizumab regimen in elderly head and neck cancer patients, presented at a major specialist conference.

Despite the sharp one day share price pullback of about 5.6% to US$12.50, Alpha Tau Medical still shows strong momentum, with a 30 day share price return of about 14.9% and a year to date share price return of about 158.8%, alongside a one year total shareholder return of about 316.7%. This suggests the recent clinical updates are being weighed against higher expectations and changing views on risk.

If Alpha Tau Medical's surge has caught your attention, it could be a good moment to see what else is moving in healthcare AI and oncology related tools via 40 healthcare AI stocks

Alpha Tau Medical now trades at roughly a 14% discount to the average analyst price target after a very strong 1 year run. Are investors prudently fading hype around early data, or mispricing the risk reward here?

Preferred Price to Book of 16.3x: Is It Justified?

With Alpha Tau Medical last closing at $12.50 and still unprofitable, the clearest valuation signal on offer is its price to book ratio, which sits at 16.3x and screens as expensive against peers.

The P/B ratio compares a company’s market value to its net assets on the balance sheet. For early stage healthcare stocks with little or no revenue, investors often lean on this metric because there are no earnings to plug into a P/E and cash flow forecasts can be difficult to assess.

In this case, Alpha Tau Medical’s P/B of 16.3x stands well above the peer group average of 6.3x and the broader US Medical Equipment industry average of 2.3x. That gap suggests the market is assigning a much higher value to Alpha Tau Medical’s assets and pipeline potential than it is to the typical company in the same industry.

For context, the Simply Wall St checks flag the stock as expensive on this preferred multiple compared both to close peers and to the wider industry. This implies expectations around future commercialization and revenue are already embedded in the price.

Result: Price-to-book of 16.3x (OVERVALUED)

However, Alpha Tau Medical still faces meaningful risks, including dependence on early clinical data and ongoing losses of about US$56.9m, which could pressure future funding needs.

Next Steps

With sentiment clearly split between Alpha Tau Medical's pipeline potential and its funding and clinical risks, it makes sense to move quickly and weigh the evidence yourself. To see the balance of concerns and reasons for optimism in one place, review the 1 key reward and 4 important warning signs

Looking for more investment ideas beyond Alpha Tau Medical?

If Alpha Tau Medical has sharpened your focus on where capital goes next, do not stop at one stock. Use the Simply Wall St Screener to surface other focused ideas before the crowd does.

• Target potential mispricings by scanning for quality companies trading below their fundamentals through the 50 high quality undervalued stocks.
• Prioritise resilience by checking out the 84 resilient stocks with low risk scores for stocks with steadier risk profiles that can help balance a concentrated portfolio.
• Hunt for fresh opportunities by using the screener containing 20 high quality undiscovered gems that many investors may be overlooking today.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.